Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$110.68+28.04%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RYTM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
IMCIVREE global sales revenue | A primary condition in Rhythm Pharmaceuticals, Inc.'s published investment case. The stated target is >= $194 million. | Improving | IMCIVREE revenue falls below $130 million in 2025 | Revenue: $92.128M FY2026-Q3; GAAP. Published target: >= $194 million. The stored target says 2025-Q4; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Nov 3, 202692,128,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making growth business, not an established compounder. The multi-year view is in watch status: commercial and regulatory progress is visible, but recent financial performance remains below its industry cohort.
The valuation is expensive versus peers, with a durable premium reflected in the evidence, while the model’s confidence is low. The expectations gap is negative, suggesting the premium may leave limited room for execution to fall short, though no valuation fragility gates have fired.
Near term, IMCIVREE growth and new market access support revenue expansion: global product revenue rose 19% from the first to the second quarter of 2026, and management anticipates a Japan launch by year-end. Pipeline progress is mixed, and rising research and selling expenses keep the business loss-making; the narrower 2026 expense range shows active cost management. A guidance cut or weakening employment data could add pressure, while the near-term miss-risk signal is quiet despite elevated industry risk.
Over the next one to three years, the thesis hinges on whether IMCIVREE’s U.S. growth and new authorizations translate into sustained commercial expansion. Clinical progress in MC4R agonists, expense discipline, and management’s ability to avoid guidance cuts are key company-specific swing factors. Healthcare-sector momentum may help the backdrop if major peers continue to report strong results, while weaker employment data could intensify concerns across the sector.
RYTM has credible commercial and regulatory progress, but its loss-making profile, elevated risk, and expensive valuation keep the multi-year thesis dependent on execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Expanded market authorization for IMCIVREE |
| The company expanded market authorization for IMCIVREE to treat more obesity types. |
| Improving |
| Failure to maintain or expand IMCIVREE market authorization by end 2026 |
Japan launch completed; HO data pending IMCIVREE launched in Japan for obesity. Phase 2 trial for acquired hypothalamic obesity shows -11.6% mean BMI reduction at 16 weeks. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Non-GAAP operating expenses | Operating expenses are guided to stay between $385M and $415M in 2026. | Intact | Operating expenses exceed $415 million in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.79 → $-0.89 · observed estimates
$0.54B → $0.57B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.79 | $539,158,000 | 10 / 16 |
| 2026-07-25 | $-0.74 | $538,995,330 | 9 / 15 |
| 2026-07-26 | $-0.74 | $538,995,330 | 9 / 15 |
| 2026-07-27 | $-0.74 | $538,995,330 | 9 / 15 |
| 2026-07-28 | $-0.74 | $538,995,330 | 9 / 15 |
| 2026-07-29 | $-0.65 | $545,758,110 | 10 / 16 |
| 2026-07-30 | $-0.68 | $545,751,463 | 8 / 11 |
| 2026-07-31 | $-0.65 | $545,758,110 | 10 / 16 |
| 2026-08-01 | $-0.68 | $545,751,463 | 9 / 12 |
| 2026-08-02 | $-0.65 | $545,758,110 | 10 / 16 |
| 2026-08-03 | $-0.68 | $545,751,463 | 9 / 12 |
| 2026-08-04 | $-0.65 | $545,758,110 | 10 / 16 |
| 2026-08-05 | $-0.47 | $552,254,150 | 9 / 16 |
| 2026-08-06 | $-0.68 | $545,751,463 | 9 / 12 |
| 2026-08-08 | $-0.67 | $561,172,362 | 7 / 12 |
| 2026-08-09 | $-0.64 | $559,546,780 | 9 / 16 |
| 2026-08-10 | $-0.64 | $559,546,780 | 9 / 16 |
| 2026-08-12 | $-0.61 | $561,109,280 | 11 / 16 |
| 2026-08-13 | $-0.67 | $561,172,362 | 7 / 12 |
| 2026-08-14 | $-0.67 | $561,172,362 | 7 / 12 |
| 2026-08-15 | $-0.67 | $561,172,362 | 8 / 12 |
| 2026-08-16 | $-0.67 | $561,172,362 | 8 / 12 |
| 2026-08-17 | $-0.67 | $561,172,362 | 8 / 12 |
| 2026-08-18 | $-0.67 | $561,172,362 | 8 / 12 |
| 2026-08-19 | $-0.67 | $561,172,362 | 8 / 12 |
| 2026-08-20 | $-0.67 | $561,110,146 | 10 / 12 |
| 2026-08-21 | $-0.67 | $561,110,146 | 10 / 12 |
| 2026-08-22 | $-0.67 | $561,110,146 | 10 / 12 |
| 2026-08-23 | $-0.67 | $561,110,146 | 10 / 12 |
| 2026-08-24 | $-0.67 | $561,110,146 | 10 / 12 |
| 2026-08-25 | $-0.67 | $561,110,146 | 10 / 12 |
| 2026-08-26 | $-0.67 | $561,110,146 | 10 / 12 |
| 2026-08-27 | $-0.67 | $561,110,146 | 10 / 12 |
| 2026-08-28 | $-0.67 | $561,110,146 | 10 / 12 |
| 2026-08-29 | $-0.67 | $560,231,184 | 10 / 12 |
| 2026-08-30 | $-0.67 | $560,231,184 | 10 / 12 |
| 2026-08-31 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-01 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-02 | $-0.67 | $560,231,184 | 11 / 13 |
| 2026-09-03 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-04 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-05 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-06 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-07 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-08 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-09 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-10 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-11 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-12 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-13 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-14 | $-0.67 | $560,231,184 | 10 / 13 |
| 2026-09-15 | $-0.66 | $554,537,066 | 10 / 13 |
| 2026-09-16 | $-0.66 | $554,537,066 | 10 / 13 |
| 2026-09-17 | $-0.66 | $554,537,066 | 10 / 13 |
| 2026-09-18 | $-0.66 | $554,537,066 | 10 / 13 |
| 2026-09-19 | $-0.66 | $554,537,066 | 10 / 13 |
| 2026-09-20 | $-0.64 | $554,537,066 | 10 / 13 |
| 2026-09-21 | $-0.64 | $554,537,066 | 10 / 13 |
| 2026-09-22 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-09-23 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-09-24 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-09-25 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-09-26 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-09-27 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-09-28 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-09-29 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-09-30 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-10-01 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-10-02 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-10-03 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-10-04 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-10-05 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-10-06 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-10-07 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-10-08 | $-0.70 | $550,407,945 | 10 / 13 |
| 2026-10-09 | $-0.65 | $558,132,945 | 10 / 13 |
| 2026-10-10 | $-0.65 | $558,132,945 | 10 / 13 |
| 2026-10-11 | $-0.65 | $558,118,117 | 10 / 13 |
| 2026-10-12 | $-0.65 | $558,118,117 | 10 / 13 |
| 2026-10-13 | $-0.64 | $559,428,816 | 10 / 13 |
| 2026-10-14 | $-0.64 | $559,428,816 | 11 / 13 |
| 2026-10-15 | $-0.64 | $559,428,816 | 11 / 14 |
| 2026-10-16 | $-0.65 | $558,782,302 | 11 / 14 |
| 2026-10-17 | $-0.65 | $558,782,302 | 11 / 14 |
| 2026-10-18 | $-0.65 | $561,856,218 | 11 / 15 |
| 2026-10-19 | $-0.65 | $561,856,218 | 11 / 15 |
| 2026-10-20 | $-0.65 | $561,856,218 | 11 / 15 |
| 2026-10-21 | $-0.65 | $561,856,218 | 11 / 15 |
| 2026-10-22 | $-0.65 | $561,856,218 | 12 / 15 |
| 2026-10-23 | $-0.65 | $561,856,218 | 12 / 15 |
| 2026-10-24 | $-0.65 | $561,856,218 | 12 / 15 |
| 2026-10-25 | $-0.65 | $561,856,218 | 12 / 15 |
| 2026-10-26 | $-0.65 | $561,856,218 | 12 / 15 |
| 2026-10-27 | $-0.65 | $561,856,218 | 12 / 15 |
| 2026-10-28 | $-0.65 | $561,856,218 | 12 / 15 |
| 2026-10-29 | $-0.65 | $561,856,218 | 12 / 15 |
| 2026-10-30 | $-0.65 | $561,905,850 | 12 / 15 |
| 2026-10-31 | $-0.65 | $561,905,850 | 12 / 15 |
| 2026-11-01 | $-0.65 | $561,905,850 | 12 / 15 |
| 2026-11-02 | $-0.65 | $561,905,850 | 12 / 15 |
| 2026-11-03 | $-0.65 | $561,905,850 | 12 / 15 |
| 2026-11-04 | $-0.89 | $567,503,761 | 11 / 15 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 17 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 5 recorded
1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.